Ukusinda komhlaza wesibindi ngo-2026: Unyango lwaseTshayina kunye neendleko-izibhedlele ezikufutshane nam 

Ukusinda komhlaza wesibindi ngo-2026 ubone ukuphucuka okubalulekileyo ngenxa yempumelelo yonyango lwe-neoadjuvant kunye nezikhokelo zeklinikhi ezihlaziyiweyo ezivela e-China. Uphononongo lwakutsha nje lubonisa ukuba indibaniselwano yamachiza amatsha asetyenziswa phambi kotyando inokuphantse iphindwe kabini ixesha abaphila ngalo abaguli ngaphandle kokuphinda kwesifo, kutshintshe umgangatho wokhathalelo lwehlabathi.

Ukuphumelela kumazinga okuSinda koMhlaza wesibindi ngo-2026

I-landscape ye-hepatocellular carcinoma (HCC) kunye ne-intrahepatic cholangiocarcinoma (ICC) yonyango iye yatshintsha ngokukhawuleza ekuqaleni kwe-2026. Kwiminyaka emininzi, umhlaza wesibindi wawudityaniswe ne-prognosis embi kunye namazinga aphezulu okuphindaphinda. Nangona kunjalo, ukusinda komhlaza wesibindi Iimetrics ngoku zichazwa ngokutsha ngolingo olungqongqo lwezonyango olusuka kumaziko ezonyango aseTshayina.

Uphononongo olubalulekileyo olupapashwe kwi New England Journal of Medicine ngoMatshi 2026 ibalaselisa utshintsho lweparadigm. Ikhokelwa ngabaphandi kwiSibhedlele saseZhongshan seYunivesithi yaseFudan, olu lingo lwamaziko amaninzi lubonise ukuba iprotocol ethile ye-neoadjuvant inokwandisa ukusinda kwesiganeko esiphakathi ukusuka kwiinyanga ezisi-8.7 ukuya kwiinyanga ezili-18. Oku kubonisa ukuphinda-phinda kabini kwexesha izigulane zihlala zingenawo umhlaza kwakhona emva konyango.

Ukubaluleka kwale datha akunakubaxwa. Ngokwembali, izinga lokusinda leminyaka emihlanu emva koqhaqho loqhaqho kwezinye iicancer zesibindi lihamba phakathi kwe-25% kunye ne-40%. Ukuhlanganiswa kwonyango olujoliswe kuyo kunye ne-immunotherapy ngaphambi kokuhlinzwa ngokukhawuleza kuba "umgangatho wokunyamekela" omtsha kwizigulane ezifanelekileyo. Le ndlela icutha amathumba kakhulu phambi kokuba imela ichukumise ulusu, ngamazinga okuphendula okujoliswe kuko afikelela malunga nama-55% kumaqela olingo.

Abaqhubi abaPhambili boPhuculo lokuSinda

• Neoadjuvant Protocols: Ukulawula unyango olucwangcisiweyo phambi kotyando ukuthoba amathumba.
• Ukudityaniswa kwe-Immunotherapy: Ukusebenzisa i-PD-1/PD-L1 inhibitors ukuze kusebenze amajoni omzimba ngokuchasene nesifo esincinci.
• Ujoliso oluchanekileyo: Ukudibanisa i-chemotherapy kunye ne-tyrosine kinase inhibitors (TKIs) ethile.
• Ukufunyanwa Kwangethuba: Uvavanyo olomeleziweyo olukhokelela kumathuba ongenelelo angaphambili.

Olu phuculo aluphelelanga kwisetingi zovavanyo. NgoJanuwari 2026, iKomishini yezeMpilo yeSizwe yaseTshayina yakhupha i Ukuxilongwa koMhlaza weSibindi okusisiseko kunye neziKhokelo zoNyango (uHlelo luka-2026). Olu xwebhu ludibanisa ubungqina obuphezulu, kubandakanywa uphando lwasekhaya lwasekhaya olupapashwe kwiijenali eziphezulu zamazwe ngamazwe, ukubonelela ngesikhokelo esigunyazisiweyo sobugcisa bokusebenza kwezonyango kwilizwe lonke.

IziKhokelo zeKlinikhi ze-2026 zaseTshayina kunye neMvumelwano yeNgcali

Ukukhutshwa kwezikhokelo zika-2026 kubonisa isiganeko esibalulekileyo kumlo wehlabathi wokulwa nomhlaza wesibindi. Ngokungafaniyo nophindaphindo lwangaphambili, inguqulelo ka-2026 ibandakanya ngokucacileyo iziphumo zamva nje ukusuka kwixesha "ekujoliswe kulo kunye ne-immune". Ihamba ngaphaya kwezigaba ezilula ze-anatomical ukubandakanya izinto ezinobungozi bebhayoloji, iqinisekisa ukuba unyango lulungelelaniswe namathuba esigulane ngasinye sokuphinda.

Uxwebhu oluyiqabane, i Imvumelwano yeNgcali kwi-Postoperative Adjuvant Therapy ye-Hepatocellular Carcinoma (uHlelo luka-2026), nayo yatyhilwa eShanghai. Ikhokelwa ngabafundi bezemfundo uFan Jia kunye noZhou Jian, le mvumelwano ijongana nomcimbi onenkani wokuphindaphinda emva kotyando, ochaphazela i-50% ukuya kwi-70% yezigulane. Imvumelwano ibonelela ngesakhelo esicwangcisiweyo sokuchonga izigulane "eziphakathi ukuya phezulu" ezixhamla kakhulu kunyango lwe-adjuvant.

Umngcipheko wokuphindaphinda

Imvumelwano ka-2026 yazisa indlela esulungekileyo yokuhlela umngcipheko wokuphindaphinda. Le stratification ibalulekile ekumiseleni ukuba isigulana sifuna unyango lwe-adjuvant ndlongo okanye sinokulawulwa ngokucupha okuqhelekileyo.

• Umngcipheko wokuPhinda kwangethuba (≤2 iminyaka): Ukuchazwa yimiba enjengamathumba amaninzi, ubukhulu becala elikhulu kune-5 cm, i-Edmondson grade III-IV, i-microvascular or macrovascular invasion, i-lymph node metastasis, i-tumor rupture, kunye nokungahambi kakuhle kwe-AFP okanye i-DCP emva kokuhlinzwa.
• Umngcipheko wokuPhinda kade (>2 iminyaka): Idla ngokunxulunyaniswa nokuqhubekeka kwesifo sesibindi endaweni yebhayoloji yethumba.
• Isicwangciso somngcipheko ophantsi: Izigulane ezine-tumor enye ≤5 cm kwaye akukho ukuhlaselwa kwe-microvascular kucetyiswa ukuba zenze iimvavanyo ezilandelwayo rhoqo kunonyango olukhawulezayo lwe-adjuvant.

Oku kutshixa ngokuthe ngqo kumaqela “aphakathi ukuya kophezulu” kuqinisekisa ukuba unyango olunamandla lugcinelwe abo balufuna kakhulu, ukwandisa ulwabiwo lwezibonelelo kunye nokunciphisa iziphumo ebezingalindelekanga ezingeyomfuneko kubantu abasengozini esezantsi. Izikhokelo zigxininisa ukuba unyango lwe-systemic anti-tumor luye lwangena kwisigaba esitsha apho ubunzima bayo kwi-adjuvant setting iye yanda kakhulu.

Unyango lweNeoadjuvant: Umgangatho oMtsha wokuKhathalela

Ingqikelelo yonyango lwe-neoadjuvant-ukunyanga umhlaza phambi kongenelelo oluphambili lotyando-luphumelele kuvavanyo oluyimfuneko ngo-2026. Ulingo olubalulekileyo olubandakanya izigulane eziyi-178 kwizibhedlele ezili-11 zase China zibonelele ngobungqina obuqinileyo obufunekayo ukuze kufakwe isamente le ndlela.

Kolu lingo, elinye iqela lafumana imijikelo emithathu ye-Gemox chemotherapy edityaniswe neyeza lonyango ekujoliswe kulo kunye ne-agent ye-immunotherapy. Iqela lolawulo lenziwa utyando olukhawulezileyo, olwalungumgangatho wemveli. Iziphumo zazizicacele: ukusinda kwesiganeko esiphakathi kwiqela elidityaniswe neziyobisi kwakuyienyanga ezili-18, xa kuthelekiswa neenyanga eziyi-8.7 kuphela zeqela lotyando.

Indlela yokwenza

Impumelelo yale cocktail ilele kuhlaselo lwayo lwe-multi-pronged kwi-tumor. I-Chemotherapy ibulala ngokuthe ngqo iiseli ezahlulahlula ngokukhawuleza. Amachiza onyango ekujoliswe kuwo anqanda iindlela ezithile ezibangela ukukhula kwethumba kunye ne-angiogenesis (ukwakheka kwesitya segazi). Amachiza e-Immunotherapy, anje nge-PD-1 inhibitors, anceda amajoni omzimba aqonde kwaye ahlasele iiseli zomhlaza ezinokuthi ziphephe ukubhaqwa.

Ngokunciphisa i-tumor ngaphambi kokuhlinzwa, oogqirha botyando banokufikelela kwimida ecacileyo (i-R0 resection), eyona nto ibalulekileyo yokuphila kwexesha elide. Ngapha koko, ukunyanga i-micrometastases kwangoko kubathintela ekusekeni indawo kwezinye iindawo zesibindi okanye umzimba ngexesha loxinzelelo lotyando.

Amanyathelo okuPhumeza kwezonyango

• Inyathelo 1: Ukuxilongwa kunye nenqanaba: I-imaging ebanzi kunye ne-biopsy yokuqinisekisa i-HCC okanye i-ICC kunye nokumisela inqanaba.
• Inyathelo lesi-2: Uvavanyo loMngcipheko: Ukuvavanya ukuhlaselwa kwe-vascular, ubukhulu be-tumor, kunye namanqanaba e-biomarker (AFP, DCP).
• Inyathelo 3: Uphononongo lweqela leeNgxoxo ezininzi (MDT): Oogqirha botyando, ii-oncologists, kunye neengcali ngemitha ziyasebenzisana ukwenza isigqibo malunga nokufaneleka kwe-neoadjuvant.
• Inyathelo 4: Ulawulo lweNeoadjuvant: Ngokuqhelekileyo imijikelo emi-3 yonyango oludityanisiweyo kwiiveki ezi-6-9.
• Inyathelo lesi-5: Ukuphonononga kwakhona: Ukwenza umfanekiso ukuvavanya ukushwabana kwethumba kunye nempendulo.
• Inyathelo lesi-6: Uqhaqho loqhaqho: Ukuqhubela phambili utyando ukuba i-tumor ihlaziywa kwaye imeko yesigulane ivumela.

Oku kuhamba komsebenzi ngoku kwamkelwe zizibhedlele eziphambili kungekuphela eTshayina kodwa zinefuthe kwiiprothokholi kwihlabathi liphela. Ukukwazi ukuguqula iimeko ezingenakulungiseka ukuba ziphinde zihlaziywe ngokunciphisa kubaluleke kakhulu kwizigulane ezinamathumba amakhulu okanye anzima.

IziCwangciso zoNyango lwe-Postoperative Adjuvant

Nasemva kotyando oluyimpumelelo, umngcipheko wokuphindaphinda uhlala ungoyena mqobo wexesha elide ukusinda komhlaza wesibindi. I-2026 Expert Consensus inikezela ngeengcebiso ezicacileyo zonyango lwe-adjuvant, ukusuka kwindlela "yobukhulu obunye" ukuya kwiyeza elichanekileyo.

Unyango lweNkqubo kwi-Adjuvant Setting

Imvumelwano iqaqambisa ukungena konyango lwenkqubo “kwixesha ekujoliswe kulo lokhuselo lomzimba.” Idatha evela kwizifundo ezibandakanya i-sintilimab kunye ne-atezolizumab kunye ne-bevacizumab (i-"T + A" irejimeni) iye yandisa ubunzima bonyango lwenkqubo kwisigaba somncedisi.

• Iindlela ezidityanisiweyo: Ubungqina bubonisa ukuba ukudibanisa iziyobisi ezijoliswe kuyo (njenge-donafenib) kunye ne-immunotherapy (njenge-tislelizumab okanye i-toripalimab) kunokuphucula ngakumbi i-prognosis kwizigulane ezinobungozi obukhulu.
• I-Immunotherapy Monotherapy: Kwizigulane ezinemingcipheko ephakathi ukuya kwephezulu, i-immune checkpoint inhibitors yodwa ibonise inzuzo ebalulekileyo kwi-Relapse-Free Survival (RFS).
• Ubude bexesha: Imvumelwano icebisa i-6 kwiinyanga ze-12 ze-systemic anti-tumor unyango kwizigulane ezinobungozi obuphakathi ukuya phezulu.

Ngokucacileyo, i-donafenib monotherapy kwizigulana ezisemngciphekweni omkhulu ibonise izinga lokusinda le-1-year relapse-free lisondela kwi-87%. Kwii-subsets ezithile zesigulane, iirejimeni ezidibeneyo ziye zatyhalela i-1-year jikelele izinga lokusinda kwi-96.7%. La manani amele umtsi omkhulu kwidatha yembali.

USukiso loNyango lweNdawo

Ngaphaya kwamachiza acwangcisiweyo, unyango lwasekhaya ludlala indima ebalulekileyo ekususeni izifo ezishiyekileyo. Izikhokelo ze-2026 zidibanisa kwaye ziphucule izibonakaliso ze-Transarterial Chemoembolization (TACE), i-Hepatic Arterial Infusion Chemotherapy (HAIC), kunye nonyango lwe-radiation.

• I-Adjuvant TACE: Icetyiswa kwizigulana ezisemngciphekweni omkhulu malunga nenyanga enye emva kotyando, olubandakanya iikhosi ezi-1 ukuya kwezi-2.
• I-Adjuvant HAIC: Ngokukodwa ukucaciswa kwezigulane ezine-Microvascular Invasion (MVI). I-HAIC yasemva kokusebenza isebenzisa irejimeni ye-FOLFOX iphucula kakhulu i-RFS kweli qela.
• Unyango ngemitha: I-Intensity-Modulated Radiation Therapy (IMRT) idweliswe njengesixhobo esiphambili kwizigulane ezinemida emxinwa yotyando (≤1 cm), i-MVI positivity, okanye i-portal vein tumor thrombus edibeneyo. Inciphisa kakhulu umngcipheko wokuphindaphinda komda.

Olu ngenelelo lwasekuhlaleni lwenzelwe ukujolisa kwibhedi yesibindi apho ukuphindaphinda kunokwenzeka ukuba kwenzeke, kusebenza njengenetha yokhuseleko kunye neenkqubo zonyango.

IiNkqubo zokuSebenza eziPhezulu: Uhlaziyo lwe-BCLC 2026

Inkqubo yesiteji yeKliniki yaseBarcelona (BCLC) isesona sikhokelo sisetyenziswa kakhulu kwihlabathi jikelele. Uhlaziyo luka-2026 lugcina i-triad yalo engundoqo ye-staging, i-prognosis, kunye nonyango kodwa yazisa umaleko wokuthatha izigqibo: isakhelo se-CUSE.

Isakhelo seSigqibo se-CUSE

Uhlaziyo lwe-2026 BCLC ludibanisa Ukuxakeka, Ukungaqiniseki, Ukuzithoba, kunye ne-Emotion (CUSE) ekwenzeni izigqibo zekliniki. Oku kuvuma ukuba ukunyanga umhlaza wesibindi akukhona nje ngokulandela i-algorithm esekelwe kubungakanani bethumba; ibandakanya ukuhamba kwiwebhu entsonkothileyo yeemeko ezithile zesigulana.

• Ukuntsokotha: Ukuvuma iimeko zezifo ezininzi kunye nokufumaneka kweendlela ezininzi zonyango.
• Ukungaqiniseki: Ukujongana nokungaqondakali kwe-prognostic kunye nokuphindaphindwa okuqhubekayo kobungqina bezonyango.
• Ukuthobela: Ubalo-mali lomahluko ngamnye kunye nezinto ezikhethwa ngabasebenzi bezonyango kunye nezigulana.
• Uvakalelo: Ukuqwalasela amava adlulileyo, okulindelweyo, kunye neenkolelo zobuqu zeqela lokhathalelo kunye nesigulana.

Esi sikhokelo sikhokela i-Multidisciplinary Teams (MDT) ukwenza izigqibo zenzululwazi, ezigxile kwisigulane. Iqinisekisa ukuba unyango "olugqwesileyo" ephepheni luhambelana nobunyani bobomi besigulane, ixabiso kunye nokugcinwa kwezinto eziphilayo.

Iingcebiso ngoNyango ngokweSigaba

Ukubandakanywa kwe-SBRT kunye ne-TARE njengezinye iindlela zonyango kwizigulana ezikwinqanaba lokuqala kwandisa ibhokisi yezixhobo kwabo bangabaviwa botyando okanye ukukhupha ngenxa yendawo ye-tumor okanye i-comorbidities. Okwangoku, isilumkiso malunga nonyango oludibeneyo lwesiqhelo kwiSigaba B sibonisa ukuzibophelela kubungqina obusekelwe kubungqina, ukuphepha ukuxhatshazwa ngokugqithisileyo kude kubekho idatha eninzi.

Abemi abaKhethekileyo: uTshintsho kunye nokuTyelwa

Imvumelwano ka-2026 ikwajongana neemeko ezikhethekileyo ezihlala zinzima kulawulo lomhlaza wesibindi, ngakumbi ukutshintshwa kwesibindi kunye nonyango lokukhupha.

IiProtokholi zoTshintsho lwesibindi

Kwizigulane ezithatha ukutshintshwa kwesibindi, ukhetho lwe-immunosuppressive regimen lubalulekile. Imvumelwano iphakamisa ukusebenzisa i-mTOR inhibitors (efana ne-sirolimus okanye i-everolimus) njengomqolo we-immunosuppression. Ngokungafaniyo ne-calcineurin inhibitors, ii-mTOR inhibitors ziye zabonwa zineepropathi zokulwa ne-tumor, ezinokuthi zincede ukunciphisa umngcipheko wokuphinda utyalwe umhlaza.

Iingqwalasela zoNyango lwe-Ablation

Ngelixa ubungqina obuphezulu bonyango lwe-adjuvant ngokukodwa emva kokuchithwa kwe-ablation lusaqokelelana, izivumelwano zokuvuma ukuba iziyobisi ezijoliswe kuzo okanye i-immunotherapy zingaqwalaselwa kwizigulane ezinobungozi obuphezulu. Ngenxa yokuba i-ablation isoloko isetyenziselwa ama-tumor amancinci, iphrofayili yomngcipheko iyahluka kwi-resection enkulu, kodwa umgaqo wokujongana nesifo se-micrometastatic uhlala ufanelekile kulabo abaneempawu ezimbi ze-pathological.

Ulawulo oluBanzi kunye noNyango lwe-Antiviral

Inkalo ebalulekileyo, edla ngokungahoywa yokuphucula ukusinda komhlaza wesibindi lulawulo lwesifo sesibindi esisisiseko. Izikhokelo ze-2026 zigxininisa ukuba unyango olusisiseko kwimvelaphi yesibindi luyimfuneko kuzo zonke izigulane.

Iimfuneko ze-Antiviral

Kwizigulane ezine-Hepatitis B Virus (HBV) ezinxulumene nomhlaza wesibindi, ukusetyenziswa kwexesha elide kwe-nucleoside analogs (njenge-tenofovir okanye i-entecavir) kunyanzelekile emva kokuhlinzwa. Ukucinezela ukuphindaphinda kwentsholongwane kunciphisa ukuvuvukala, kuthintela ukuthotywa kwesibindi, kwaye kunciphisa umngcipheko we-de novo carcinogenesis kwizicubu zesibindi eziseleyo.

Indima yoNyango lweNdabu lwanamhlanje

Ekudityanisweni okuphawulekayo kwamayeza emveli kunye nanamhlanje, ukuvumelana kuncoma ukusetyenziswa kwe-Huaier granules emva kokuhlinzwa okukhulu. Uqwalaselo lwezonyango lucebisa ukuba olu lungiselelo lwangoku lweyeza laseTshayina lunokunceda ukunqanda ukuphindaphinda kwaye lwandise ukusinda ngokubanzi, lunikezela ngokhuseleko olongezelelweyo kwizigulana ezilulamayo.

IiProtokholi zokuHlola eziPhuculweyo

Amaqhinga okulandelela aphuculwe, ngakumbi kumaqela asemngciphekweni ophakathi ukuya kophezulu. Isindululo sesokulandelela ubuncinane qho kwiinyanga ezintathu. Ngaphaya komfanekiso oqhelekileyo (CT okanye MRI), izikhokelo zicebisa ukuba apho iimeko zivuma, ubugcisa be-biopsy obumanzi obunje ngeCirculating Tumor Cells (CTC) kunye ne-circulating tumor DNA (ctDNA) kufuneka busetyenziswe.

• CTC/ctDNA Monitoring: Ezi zixhobo ziyakwazi ukubona iimpawu zemolekyuli zokuphindaphinda iinyanga ngaphambi kokuba zibonakale kwiiskena, ezivumela ukungenelela kwangaphambili.
• Ukukhangelwa kweBiomarker: Ukubekw'esweni rhoqo kwe-AFP kunye nenqanaba le-DCP lihlala lilitye lesiseko lokucupha.

Ukufumana izibhedlele kunye namaZiko oNyango akufutshane nawe

Ukufikelela kukhathalelo olukhethekileyo ngumba omiselweyo kwiziphumo zokusinda. Izigulana ezifuna iiprothokholi zamva nje, kubandakanywa iirejimeni ze-neoadjuvant kunye nonyango oluphezulu lwasekhaya oluchazwe ngasentla, kufuneka bajonge amaziko anamasebe azinikeleyo e-hepatobiliary oncology.

Yintoni omawuyijonge esibhedlele

• Iqela lezinto ezininzi (MDT): Qinisekisa ukuba isibhedlele sinenkqubo ye-MDT esesikweni apho oogqirha botyando, ii-oncologists zonyango, ii-radiologists, kunye neengcali zezifo zihlola iimeko kunye.
• Ufikelelo kulingo lwezonyango: Izibhedlele ezikumgangatho ophezulu zihlala zithatha inxaxheba kulingo lwezonyango lwehlabathi okanye lwesizwe, lubonelela ngokufikelela kumayeza akumgangatho ophezulu phambi kokuba afumaneke ngokubanzi.
• Ubuchwephesha obukwinqanaba eliphezulu: Ukufumaneka kwe-SBRT, i-HAIC, kunye nobuchule botyando obuntsonkothileyo obufana ne-laparoscopic okanye i-robotic yesibindi sokuphinda kuphindwe.
• Umthamo kunye namava: Amaziko omthamo ophezulu ngokubanzi anika ingxelo yezinga elingcono lobunzima kunye neziphumo zokusinda kuqhaqho olunzima lwesibindi.

E-China, amaziko afana neSibhedlele saseZhongshan seYunivesithi yaseFudan, iSibhedlele seCancer se-Chinese Academy yeSayensi yezoNyango, kunye neSibhedlele sokuQala esiBambiseneyo se-USTC sikhokelela ekuphunyezweni kwezi zikhokelo ze-2026. Ngamazwe ngamazwe, izigulana kufuneka zifune amaziko omhlaza atyunjwe yi-NCI okanye izibhedlele zaseyunivesithi ezineenkqubo ezinamandla ze-hepatobiliary.

Ukuqwalaselwa kweendleko kunye nokuFikelela

Ngelixa ukuqhubela phambili kwezonyango ngo-2026 kuyathembisa, iindleko zihlala ziyinkxalabo ebalulekileyo kwizigulana ezininzi. Ukutshintshela kwindibaniselwano ye-immunotherapy kunye nonyango olujoliswe kuyo kunokunyusa umthwalo wemali wonyango.

I-inshurensi kunye ne-Inshurensi

E-China, amaninzi amachiza acetyiswayo, kubandakanywa i-PD-1 inhibitors yasekhaya kunye ne-TKIs, afakwe kwikhathalogu ye-inshurensi yonyango yelizwe, ukunciphisa kakhulu iindleko eziphuma epokothweni kwizigulane. Le ntshukumo yomgaqo-nkqubo ibaluleke kakhulu ekuqinisekiseni ukuba "isisombululo sesizwe" sokuthintela umhlaza wesibindi kunye nokulawula sifikeleleke kuluntu olubanzi.

Kwihlabathi jikelele, ukhuseleko luyahluka ngokwelizwe kunye nomnikezeli we-inshurensi. Izigulane ziyakhuthazwa ukuba:

• Dibana nabacebisi ngezemali basesibhedlele kwangethuba kwinkqubo yocwangciso lonyango.
• Phanda ngeenkqubo zoncedo lwezigulane ezinikezelwa ziinkampani ezixuba amayeza.
• Phonononga ukufaneleka kulingo lwezonyango, oluhlala luhlawula iindleko zamachiza ophando kunye novavanyo olunxulumeneyo.

Impembelelo yezoQoqosho yexesha elide

Kubalulekile ukujonga iindleko zonyango kumxholo wokuphila ixesha elide. Unyango olusebenzayo lwe-neoadjuvant kunye ne-adjuvant oluthintela ukuphindaphinda ekugqibeleni lunokunciphisa iindleko ezipheleleyo zokunyamekela ngokuphepha unyango lwe-salvage ebiza kakhulu, ukulaliswa esibhedlele ngokuphindaphindiweyo, kunye nokunyamekela okuhambelana nesifo esiphezulu, esiqhubekayo.

Izikhokelo zexesha elizayo kunye noPhando oluqhubekayo

Intsimi yonyango lomhlaza wesibindi ikhula ngesantya esingazange sibonwe ngaphambili. Izikhokelo ze-2026 ziyi-snapshot yolwazi lwangoku, kodwa uphando luyaqhubeka nokutyhala imida. Ungeniso lwakutsha nje kwiNtlanganiso yoNyaka ka-2026 ye-ASCO evela kumaziko afana neSibhedlele saseZhongnan sibonisa imida esakhulayo.

IiTekhnoloji ezisakhulayo

• I-Lattice Radiotherapy: Ukuphonononga ukhuseleko kunye nokusebenza kakuhle kweLattice Stereotactic Flash Radiotherapy kumathumba esibindi amakhulu angenakucocwa (≥10 cm).
• Iintsholongwane ze-Oncolytic: Ulingo lwenqanaba lokuqala luphanda iinaliti ze-intratumoral ezilandelelanayo zenoveli yeentsholongwane ze-oncolytic ezidityaniswe nezinye ii-arhente zamathumba aqinileyo.
• Metallic Death Induction: Uphando kwi-metabolites efana ne-alpha-ketoglutarate eyenza i-ferroptosis (ukufa kwe-iron-exhomekeke kwi-iron) ukunyusa uvakalelo lwerediyo kumhlaza wesisu.

Ezi nguqulelo zicebisa ukuba inkcazo ye ukusinda komhlaza wesibindi iya kuqhubeka nokuphucula. Ukudityaniswa kokuqonda kwe-metabolic reprogramming kunye nesizukulwana esilandelayo sobuchule beradiation buthembisa ukujongana nezona ndlela zixhathisayo zesi sifo.

Isiphelo: Ixesha elitsha leThemba

Unyaka ka-2026 uphawula inguquko kumlo ochasene nomhlaza wesibindi. Ngokupapashwa kwezikhokelo zikazwelonke ezihlaziyiweyo, ukuqinisekiswa kweendlela zonyango ezidibeneyo ze-neoadjuvant, kunye nokucocwa kweemodeli zokucwangciswa komngcipheko, izigulane namhlanje zineenketho ezisebenzayo kunanini ngaphambili. Ukuphindwa kabini kokusinda ngaphandle kwesiganeko kulingo lwakutsha nje kunika ithemba elibambekayo apho bekukhe kwakho ithuba elilinganiselweyo.

Ukususela ekusetyenzisweni ngokuchanekileyo kweerejimeni "ekujoliswe kuzo kunye ne-immune" ukuya kulawulo olupheleleyo lwesifo sesibindi esisisiseko, indlela eya phambili icacile. Impumelelo ixhomekeke ekubhaqweni kwangethuba, ukufikelela kukhathalelo olukhethekileyo lwezifundo ezininzi, kunye nokubambelela kwiiprothokholi ezisekwe kubungqina bamva nje. Njengoko uphando luqhubeka nokutyhila ubunzima bebhayoloji yomhlaza wesibindi, i-trajectory ye ukusinda komhlaza wesibindi ikhomba ngokuthe chu ukuya phezulu, iguqula uxilongo olubulalayo lube yinto elawulekayo, kwaye ehlala inyangeka, imeko.

Izigulane kunye neentsapho ziyakhuthazwa ukuba zibandakanyeke ngokusebenzayo kunye namaqela abo okhathalelo lwempilo, babuze malunga nezikhokelo zamva nje, kwaye baphonononge zonke iindlela zonyango ezikhoyo. Ukudityaniswa kobuchule beklinikhi yaseTshayina kunye nentsebenziswano yezenzululwazi yehlabathi kudale isakhelo esomeleleyo sokoyisa umhlaza wesibindi, isigulana esinye ngexesha.